The company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008.
VGX-3100 is said to be the first of the company’s several proprietary SynCon DNA vaccine candidates delivered by its Cellectra electroporation device planned to enter Phase I clinical testing.
Joseph Kim, president and CEO of VGX, said: “We are pleased with the FDA’s acceptance of our VGX-3100 investigational new drug (IND) application for treating cervical cancer. This accomplishment further demonstrates the potential and efficiency of our DNA-based product development platform.”